LATTUADA, Emanuela
LATTUADA, Emanuela
'High' antiretroviral deintensification strategy and cellular HIV DNA levels
2020-01-01 Lanzafame, Massimiliano; Lattuada, Emanuela; Vincenzi, Marcello; Vecchi, Marta; Luise, Dora; Diani, Erica; Gibellini, Davide
Acute mediastinitis: a severe complication of transdermal therapy in a patient with ischaemic heart disease. A case report.
2003-01-01 Faggian, Federica; Lattuada, Emanuela; Lanzafame, Massimiliano; Trevenzoli, Marco; Cattelan, Am; Concia, Ercole
Darunavir/ritonavir 600/100 mg once daily: it's time for larger non-inferiority randomized trials
2018-01-01 Nicole', Stefano; Lanzafame, M; Cucchetto, Giulia; Rigo, F; Lattuada, E; Concia, E
Discontinuation of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy: clinical implications in patients on CD4 T-cell-guided treatment interruption.
2007-01-01 Lanzafame, Massimiliano; Lattuada, Emanuela; Gottardi, Martina; Antolini, Dario; Concia, Ercole; Vento, Sandro
Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient
2017-01-01 Lanzafame, Massimiliano; Lattuada, Emanuela; Nicole', Stefano; Rigo, Fabio; Cucchetto, Giulia; Concia, Ercole; Vento, Sandro
Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients
2019-01-01 Rizzardo, Sebastiano; Lanzafame, Massimiliano; Lattuada, Emanuela; Luise, Dora; Vincenzi, Marcello; Tacconelli, Evelina; Vento, Sandro
Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life
2018-01-01 Lattuada, Emanuela; Lanzafame, Massimiliano; Nicolè, Stefano; Rigo, Fabio; Cucchetto, Giulia; Concia, Ercole; Vento, Sandro
Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies/mL HIV RNA Load
2016-01-01 Lanzafame, Massimiliano; Gibellini, Davide; Lattuada, Emanuela; Signoretto, Caterina; Mazzi, Romualdo; Concia, Ercole; Vento, Sandro
Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients
2017-01-01 Rigo, F; Cucchetto, G; Lanzafame, Massimiliano; Nicolè, S; Lattuada, Emanuela; Concia, Ercole; Vento, Sandro
Efavirenz dose reduction in HIV-infected patients: a long-term follow-up
2014-01-01 Lanzafame, Massimiliano; Lattuada, Emanuela; Cucchetto, Giulia; Concia, Ercole; Vento, S.
Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients
2019-01-01 Nicolè, Stefano; Lanzafame, Massimiliano; Lattuada, Emanuela; Luise, Dora; Vecchi, Marta; Tacconelli, Evelina; Vento, Sandro
Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study
2019-01-01 Rizzardo, Sebastiano; Lanzafame, Massimiliano; Lattuada, Emanuela; Bragantini, Damiano; Nicolè, Stefano; Calza, Leonardo; Tacconelli, Evelina
Efficacy and safety of TAM-sparing antiretroviral regimens in naive HIV-positive patients
2009-01-01 Gottardi, Martina; Lanzafame, Massimiliano; Lattuada, Emanuela; Soldani, F.; Boccafoglio, F.; Concia, Ercole
Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up
2015-01-01 Lanzafame, Massimiliano; Lattuada, Emanuela; Rigo, Fabio; Ferrari, Anna; Hill, Andrew; Vento, Sandro
Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: a case report.
2003-01-01 Lanzafame, Massimiliano; Trevenzoli, Marco; Lattuada, Emanuela; Faggian, Federica; Vento, Sandro; Concia, Ercole
Histoplasmosis in two human immunodeficiency virus-positive immigrants to Italy: clinical features and management in the highly active antiretroviral therapy era.
2004-01-01 Faggian, Federica; Lanzafame, Massimiliano; Lattuada, Emanuela; Brugnaro, P; Carretta, Giovanni; Cadrobbi, P; Concia, Ercole
Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir
2018-01-01 Lanzafame, M; Nicole, S; Rizzardo, S; Piacentini, D; Chiesi, S; Lattuada, E; Diani, E; Carelli, M; Vento, S; Gibellini, D
Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor
2020-01-01 Piacentini, Daniela; Lanzafame, Massimiliano; Rizzardo, Sebastiano; Chiesi, Sheila; Lattuada, Emanuela; Mehrabi, Sara; Zamboni, Giulia; Mazzi, Romualdo; Tacconelli, Evelina; Vento, Sandro
Is there a role for TNF-alpha in HIV1-associated lipodystrophy?
2003-01-01 Lanzafame, Massimiliano; Faggian, Federica; Lattuada, Emanuela; D., Ramarli; Concia, Ercole; Vento, Sandro
Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report
2019-01-01 Chiesi, Sheila; Rizzardo, Sebastiano; Piacentini, Daniela; Be, Giorgia; Lattuada, Emanuela; Tacconelli, Evelina; Lanzafame, Massimiliano
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 'High' antiretroviral deintensification strategy and cellular HIV DNA levels | 1-gen-2020 | Lanzafame, Massimiliano; Lattuada, Emanuela; Vincenzi, Marcello; Vecchi, Marta; Luise, Dora; Diani, Erica; Gibellini, Davide | |
| Acute mediastinitis: a severe complication of transdermal therapy in a patient with ischaemic heart disease. A case report. | 1-gen-2003 | Faggian, Federica; Lattuada, Emanuela; Lanzafame, Massimiliano; Trevenzoli, Marco; Cattelan, Am; Concia, Ercole | |
| Darunavir/ritonavir 600/100 mg once daily: it's time for larger non-inferiority randomized trials | 1-gen-2018 | Nicole', Stefano; Lanzafame, M; Cucchetto, Giulia; Rigo, F; Lattuada, E; Concia, E | |
| Discontinuation of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy: clinical implications in patients on CD4 T-cell-guided treatment interruption. | 1-gen-2007 | Lanzafame, Massimiliano; Lattuada, Emanuela; Gottardi, Martina; Antolini, Dario; Concia, Ercole; Vento, Sandro | |
| Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient | 1-gen-2017 | Lanzafame, Massimiliano; Lattuada, Emanuela; Nicole', Stefano; Rigo, Fabio; Cucchetto, Giulia; Concia, Ercole; Vento, Sandro | |
| Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients | 1-gen-2019 | Rizzardo, Sebastiano; Lanzafame, Massimiliano; Lattuada, Emanuela; Luise, Dora; Vincenzi, Marcello; Tacconelli, Evelina; Vento, Sandro | |
| Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life | 1-gen-2018 | Lattuada, Emanuela; Lanzafame, Massimiliano; Nicolè, Stefano; Rigo, Fabio; Cucchetto, Giulia; Concia, Ercole; Vento, Sandro | |
| Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies/mL HIV RNA Load | 1-gen-2016 | Lanzafame, Massimiliano; Gibellini, Davide; Lattuada, Emanuela; Signoretto, Caterina; Mazzi, Romualdo; Concia, Ercole; Vento, Sandro | |
| Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients | 1-gen-2017 | Rigo, F; Cucchetto, G; Lanzafame, Massimiliano; Nicolè, S; Lattuada, Emanuela; Concia, Ercole; Vento, Sandro | |
| Efavirenz dose reduction in HIV-infected patients: a long-term follow-up | 1-gen-2014 | Lanzafame, Massimiliano; Lattuada, Emanuela; Cucchetto, Giulia; Concia, Ercole; Vento, S. | |
| Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients | 1-gen-2019 | Nicolè, Stefano; Lanzafame, Massimiliano; Lattuada, Emanuela; Luise, Dora; Vecchi, Marta; Tacconelli, Evelina; Vento, Sandro | |
| Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study | 1-gen-2019 | Rizzardo, Sebastiano; Lanzafame, Massimiliano; Lattuada, Emanuela; Bragantini, Damiano; Nicolè, Stefano; Calza, Leonardo; Tacconelli, Evelina | |
| Efficacy and safety of TAM-sparing antiretroviral regimens in naive HIV-positive patients | 1-gen-2009 | Gottardi, Martina; Lanzafame, Massimiliano; Lattuada, Emanuela; Soldani, F.; Boccafoglio, F.; Concia, Ercole | |
| Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up | 1-gen-2015 | Lanzafame, Massimiliano; Lattuada, Emanuela; Rigo, Fabio; Ferrari, Anna; Hill, Andrew; Vento, Sandro | |
| Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: a case report. | 1-gen-2003 | Lanzafame, Massimiliano; Trevenzoli, Marco; Lattuada, Emanuela; Faggian, Federica; Vento, Sandro; Concia, Ercole | |
| Histoplasmosis in two human immunodeficiency virus-positive immigrants to Italy: clinical features and management in the highly active antiretroviral therapy era. | 1-gen-2004 | Faggian, Federica; Lanzafame, Massimiliano; Lattuada, Emanuela; Brugnaro, P; Carretta, Giovanni; Cadrobbi, P; Concia, Ercole | |
| Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir | 1-gen-2018 | Lanzafame, M; Nicole, S; Rizzardo, S; Piacentini, D; Chiesi, S; Lattuada, E; Diani, E; Carelli, M; Vento, S; Gibellini, D | |
| Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor | 1-gen-2020 | Piacentini, Daniela; Lanzafame, Massimiliano; Rizzardo, Sebastiano; Chiesi, Sheila; Lattuada, Emanuela; Mehrabi, Sara; Zamboni, Giulia; Mazzi, Romualdo; Tacconelli, Evelina; Vento, Sandro | |
| Is there a role for TNF-alpha in HIV1-associated lipodystrophy? | 1-gen-2003 | Lanzafame, Massimiliano; Faggian, Federica; Lattuada, Emanuela; D., Ramarli; Concia, Ercole; Vento, Sandro | |
| Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report | 1-gen-2019 | Chiesi, Sheila; Rizzardo, Sebastiano; Piacentini, Daniela; Be, Giorgia; Lattuada, Emanuela; Tacconelli, Evelina; Lanzafame, Massimiliano |